Vial is a San Francisco-based, tech-enabled Contract Research Organization (CRO) led by CEO Simon Burns. The company offers a technology platform that powers clinical trials end-to-end from site startup to database lock. Its platform is made up of three key components: a Site Startup platform, an eSource platform, and a Patient Recruiting platform. Vial operates across multiple therapeutic areas including dermatology, ophthalmology, oncology, gastroenterology, neurology, and cardiology. The company has over 125 employees. It announced a $67M Series B and intends to use the funds to accelerate the clinical development of medicines.

Total raised

$67M

Funding rounds

1

Latest round

Series B

Latest activity

Nov 2022